" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Announces Exclusive Agreement with Julphar Diabetes

Published: Wednesday, August 08, 2012
Last Updated: Wednesday, August 08, 2012
Bookmark and Share
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.

Merck Millipore announced an exclusive agreement to sell recombinant human insulin manufactured by the United Arab Emirates-based pharmaceutical production company Julphar Diabetes. The insulin is of non-animal origin and will be marketed under Merck Millipore's CellPrime™ brand name, complementing the company's range of non-animal origin supplements for cell culture biomanufacturing.
 
CellPrime™ Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines. It also effectively enhances cell growth rate and therapeutic protein production, while preventing morphological abnormalities of the cells.
 
"CellPrime™ Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety," said Burghard Freiberg, Senior Vice President Pharm Chemicals Solutions. "Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective."
 
Joe Saldanha, GM of Julphar Diabetes said, "This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the Life Science sector.''
 
Julphar Diabetes is the division of Julphar that manages the manufacturing and commercialization of diabetes products. The Julphar Diabetes facility (Julphar XI) is built in accordance with the latest EMEA regulations, utilizing the best available technologies in the market to comply with the latest international quality standards.
 
Merck Millipore partnered with Julphar Diabetes as its source for recombinant human insulin as the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Introduces Enhancements to its EMPROVE® Program
Instant, online access to regulatory and technical information on portfolio of 400 products.
Thursday, September 17, 2015
Merck Millipore Enters Into Agreement with Singulex
Acquiring exclusive worldwide rights to Singulex’s SMC™ technology - instruments, assays and services - for research applications.
Thursday, May 28, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Princeton’s Dr Bonnie Bassler Receives 2014 Alice C. Evans Award
Merck Millipore congratulates winner of the Alice C. Evans award for leadership in clinical microbiology.
Thursday, May 22, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Introduces the Lab Solutions Virtual Conference: “Complete Solutions for Food Safety Analysis.”
Merck Millipore, the Life Science division of Merck KGaA has announced the first Lab Solutions Virtual Conference on November 19 and 20, 2013.
Tuesday, November 05, 2013
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Opens New R&D Center
Facility fosters company's focus on Bioavailability Enhancement.
Monday, July 15, 2013
Merck Millipore Introduces the Lab Water Virtual Conference
“The Lab of Tomorrow, Bringing the Future to Life Today”.
Wednesday, May 22, 2013
Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!